<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03383133</url>
  </required_header>
  <id_info>
    <org_study_id>2017-8685</org_study_id>
    <nct_id>NCT03383133</nct_id>
  </id_info>
  <brief_title>Studies of Sulfur Metabolism in Humans</brief_title>
  <official_title>Allosteric Regulation of Cytosolic Sulfotransferases in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albert Einstein College of Medicine, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Albert Einstein College of Medicine, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study test whether the NSAID allosteric site of human sulfotransferase 1A1 (SULT1A1) is
      operative in humans. The study will test the effects of mefenamic acid (MEF) on the
      sulfonation of acetaminophen (APAP, a SULT1A1 specific substrate) and dehydroepiandrosterone
      (DHEA, a SULT2A1 substrate). If the allosteric site is active in vivo, MEF is predicted to
      result in a decrease in sulfonation of APAP (MEF inhibits SULT with high affinity (Ki = 23
      nM), and to have no effect on sulfonation of the DHEA (MEF has little or no effect on SULT2A1
      activity).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      No patient registries associated with this study.

      A single, therapeutic dose of acetaminophen (APAP, 1.0 g)) or dehydroepiandrosterone (DHEA,
      75 mg) is taken orally (with 375 ml of water) either alone or simultaneously with a single,
      oral, therapeutic dose of mefenamic acid (MEF, 0.75 g). In total, 5 experiments will be
      performed: 1, APAP alone; 2, DHEA alone; 3, MEF alone; 4, APAP + MEF; and 5, DHEA + MEF. Each
      experiment will be performed in duplicate. Compounds will be taken prior to eating breakfast.
      One hour later, the patient has a light breakfast (Cheerios and milk, and a cup of coffee)
      and eats normally thereafter. Urine samples are collected at 15', 30', 1 h, 2h, 3h, 4h, 5 h,
      6h, 7h, 8h, 9h, 10h, 11h, and 12h intervals following dosing. The study subject will attempt
      to completely empty their bladder at each urine-collection time point. The samples are
      weighed. A 10 ml aliquot is taken from each time point and the aliquots are stored at -20 °C.
      Samples (0.5 ml) are then transferred to NMR tubes and NMR spectra are taken to assess drug
      metabolites in urine. Proton NMR will be performed using the 600 MHz instrument in the
      Einstein facility.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2018</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This study will involve only a single individual.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acetaminophen and Dehydroepiandrosterone Conjugates</measure>
    <time_frame>15min, 30min, 1hr, 2hr, 3hr, 4hr, 5hr, 6hr, 7hr, 8hr, 9hr, 10hr, 11hr, and 12hr following administration.</time_frame>
    <description>Proton NMR Signals will be used to quantitate conjugates of acetaminophen and dehydroepiandrosterone in urine.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">1</enrollment>
  <condition>Metabolic Side Effects of Drugs</condition>
  <arm_group>
    <arm_group_label>SULT Allosteric Inhibition</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single, therapeutic dose of acetaminophen (1.0 g)) or dehydroepiandrosterone (75 mg) is taken orally (with 375 ml of water) either alone or simultaneously with a single, oral, therapeutic dose of mefenamic acid (0.75 g).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SULT Allosteric Inhibition</intervention_name>
    <description>A single, therapeutic dose of acetaminophen (APAP, 1.0 g)) or dehydroepiandrosterone (DHEA, 75 mg) is taken orally (with 375 ml of water) either alone or simultaneously with a single, oral, therapeutic dose of mefenamic acid (MEF, 0.75 g). In total, 5 experiments will be performed. Each experiment is performed in duplicate. Compounds are taken prior to eating breakfast. One hour later, the patient has a light breakfast and eats normally thereafter. Urine samples are collected at 15', 30', 1 h, 2h, 3h, 4h, 5 h, 6h, 7h, 8h, 9h, 10h, 11h, and 12h intervals following dosing. The samples are weighed. A 10 ml aliquot is taken from each time point and the aliquots are stored at -20 °C. Samples (0.5 ml) are then transferred to NMR tubes spectra are taken to assess drug metabolites in urine.</description>
    <arm_group_label>SULT Allosteric Inhibition</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Gender - one male

          -  Age - 61 y.o.

          -  Healthy

          -  Agreed to sign the consent form

        Exclusion criteria:

        ● None
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>61 Years</minimum_age>
    <maximum_age>61 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas S Leyh, Ph. D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Albert Einstein College of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas S Leyh, Ph. D.</last_name>
    <phone>914-262-3882</phone>
    <email>tsleyh@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ian T Cook, Ph. D.</last_name>
    <phone>718-430-2858</phone>
    <email>icook1723@gmail.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Falany JL, Macrina N, Falany CN. Regulation of MCF-7 breast cancer cell growth by beta-estradiol sulfation. Breast Cancer Res Treat. 2002 Jul;74(2):167-76.</citation>
    <PMID>12186377</PMID>
  </reference>
  <reference>
    <citation>Parker CR Jr. Dehydroepiandrosterone and dehydroepiandrosterone sulfate production in the human adrenal during development and aging. Steroids. 1999 Sep;64(9):640-7. Review.</citation>
    <PMID>10503722</PMID>
  </reference>
  <reference>
    <citation>Cook IT, Duniec-Dmuchowski Z, Kocarek TA, Runge-Morris M, Falany CN. 24-hydroxycholesterol sulfation by human cytosolic sulfotransferases: formation of monosulfates and disulfates, molecular modeling, sulfatase sensitivity, and inhibition of liver x receptor activation. Drug Metab Dispos. 2009 Oct;37(10):2069-78. doi: 10.1124/dmd.108.025759. Epub 2009 Jul 9.</citation>
    <PMID>19589875</PMID>
  </reference>
  <reference>
    <citation>Visser TJ. Role of sulfation in thyroid hormone metabolism. Chem Biol Interact. 1994 Jun;92(1-3):293-303. Review.</citation>
    <PMID>8033262</PMID>
  </reference>
  <reference>
    <citation>Eisenhofer G, Coughtrie MW, Goldstein DS. Dopamine sulphate: an enigma resolved. Clin Exp Pharmacol Physiol Suppl. 1999 Apr;26:S41-53. Review.</citation>
    <PMID>10386253</PMID>
  </reference>
  <reference>
    <citation>Swann J, Murry J, Young JA. Cytosolic sulfotransferase 1A1 regulates HIV-1 minus-strand DNA elongation in primary human monocyte-derived macrophages. Virol J. 2016 Feb 24;13:30. doi: 10.1186/s12985-016-0491-9.</citation>
    <PMID>26906565</PMID>
  </reference>
  <reference>
    <citation>Yalcin EB, More V, Neira KL, Lu ZJ, Cherrington NJ, Slitt AL, King RS. Downregulation of sulfotransferase expression and activity in diseased human livers. Drug Metab Dispos. 2013 Sep;41(9):1642-50. doi: 10.1124/dmd.113.050930. Epub 2013 Jun 17.</citation>
    <PMID>23775849</PMID>
  </reference>
  <reference>
    <citation>Wang T, Cook I, Leyh TS. The NSAID allosteric site of human cytosolic sulfotransferases. J Biol Chem. 2017 Dec 8;292(49):20305-20312. doi: 10.1074/jbc.M117.817387. Epub 2017 Oct 16.</citation>
    <PMID>29038294</PMID>
  </reference>
  <reference>
    <citation>Riches Z, Stanley EL, Bloomer JC, Coughtrie MW. Quantitative evaluation of the expression and activity of five major sulfotransferases (SULTs) in human tissues: the SULT &quot;pie&quot;. Drug Metab Dispos. 2009 Nov;37(11):2255-61. doi: 10.1124/dmd.109.028399. Epub 2009 Aug 13.</citation>
    <PMID>19679676</PMID>
  </reference>
  <reference>
    <citation>Nagar S, Walther S, Blanchard RL. Sulfotransferase (SULT) 1A1 polymorphic variants *1, *2, and *3 are associated with altered enzymatic activity, cellular phenotype, and protein degradation. Mol Pharmacol. 2006 Jun;69(6):2084-92. Epub 2006 Mar 3.</citation>
    <PMID>16517757</PMID>
  </reference>
  <reference>
    <citation>Falany CN, Vazquez ME, Kalb JM. Purification and characterization of human liver dehydroepiandrosterone sulphotransferase. Biochem J. 1989 Jun 15;260(3):641-6.</citation>
    <PMID>2764897</PMID>
  </reference>
  <reference>
    <citation>Cook I, Wang T, Falany CN, Leyh TS. The allosteric binding sites of sulfotransferase 1A1. Drug Metab Dispos. 2015 Mar;43(3):418-23. doi: 10.1124/dmd.114.061887. Epub 2014 Dec 22.</citation>
    <PMID>25534770</PMID>
  </reference>
  <reference>
    <citation>Vietri M, De Santi C, Pietrabissa A, Mosca F, Pacifici GM. Inhibition of human liver phenol sulfotransferase by nonsteroidal anti-inflammatory drugs. Eur J Clin Pharmacol. 2000 Apr;56(1):81-7.</citation>
    <PMID>10853883</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2017</study_first_submitted>
  <study_first_submitted_qc>December 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2017</study_first_posted>
  <last_update_submitted>December 22, 2017</last_update_submitted>
  <last_update_submitted_qc>December 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Albert Einstein College of Medicine, Inc.</investigator_affiliation>
    <investigator_full_name>Thomas Leyh</investigator_full_name>
    <investigator_title>Professor of Microbiology and Immunology</investigator_title>
  </responsible_party>
  <keyword>sulfotransferase</keyword>
  <keyword>metabolism</keyword>
  <keyword>acetaminophen</keyword>
  <keyword>dehydroepiandrosterone</keyword>
  <keyword>mefenamic acid</keyword>
  <keyword>allostery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Drug-Related Side Effects and Adverse Reactions</mesh_term>
    <mesh_term>Metabolic Side Effects of Drugs and Substances</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Mefenamic Acid</mesh_term>
    <mesh_term>Dehydroepiandrosterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>This study will determine the levels acetaminophen and dehydroepiandrosterone conjugates in the urine of a single individuals. The levels will be published and</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

